5 Extreme Value Stocks to Buy Now

4. Viatris Inc. (NASDAQ:VTRS)

Viatris Inc. (NASDAQ:VTRS) is covered by 12 analysts on Wall Street with a medium price target of $16, suggesting 12.36% upside from current levels. On February 27, Truist Financial analyst Les Sulewski raised the firm’s price target on the stock from $16 to $18 while reaffirming a Buy rating. The price target came just after the company announced its fourth-quarter financial results.

Viatris Inc. (NASDAQ:VTRS) posted its Q4 fiscal 2025 results on February 26, reporting revenue of $3.7 billion. This reflects 1% year-over-year growth when excluding the impact related to the Indore facility. The company generated $14.3 billion in revenue for the full year 2025. During the year, the company returned more than $1 billion to shareholders.

Free cash flow for the year reached $2.2 billion, excluding costs related to transactions. Looking ahead, management expects earnings and revenue to improve in the second half of 2026, supported by upcoming product launches and seasonality. Management expects to continue the current momentum in 2026, forecasting around 2% growth in both adjusted EBITDA and total revenue. Viatris Inc. (NASDAQ:VTRS) also anticipates generating between $450 million and $550 million in revenue from new product launches during the year.

Viatris Inc. (NASDAQ:VTRS) is a healthcare company operating across Japan, Europe, Hong Kong, Africa, North America, Australia, the Middle East, New Zealand, Taiwan, Latin America, China, and the rest of Asia. The company operates through the JANZ, Developed Markets, Emerging Markets, and Greater China segments.